Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials.
Ilenia Lorenza CalcaterraRoberta LupoliAlessandro Di MinnoMatteo Nicola Dario Di MinnoPublished in: European journal of clinical investigation (2022)
In patients with severe HTG, volanesorsen is associated with a significant reduction in TG, VLDL-C, Apo-B48 and non-HDL-C and increment of HDL-C as compared to placebo. Documented efficacy is accompanied by an acceptable safety profile.
Keyphrases